Introducing BIOiSIMTM

BIOiSIMTM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.

“At a time when numerous smaller organizations are over-selling their AI efforts as cure-alls, I found VSL's down-to-earth but competent and insightful approach very refreshing...I would not hesitate to recommend them for organizations looking for professional and knowledgeable external ML solutions.”
- Associate Director at Genentech

BIOiSIMTM Offerings

We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses.


Our Proven Platform
  • Scalable Models

    Our models are built on data from thousands of compounds across 7 species, leading to a robustness rarely seen in the industry.

  • Great Translability

    With a focus on human outcomes, the platform has at its core a translability engine that transforms insights across species.

  • Early Insights

    The BIOiSIMTM platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.

  • Continuous Development

    The team employees a continuous improvement process to iterate on data stability, improve models, and provide an always up-to-date software service.

  • Artificial Intelligence and Mechanistic Models

    VSL has shown that the best models are developed by using a hybrid mixed-model approach to drug insights, leading to greater accuracy and scalability.

  • Fast Model Development

    The flexibility of the platform and generations of customer-ready tools allows for development of custom models and validations within weeks.

The Solution

VeriSIM has developed a platform that integrates machine learning with robust models of in vivo pharmacokinetics and pharmacodynamics, enabling faster model development, more accurate prediction, and higher scalability.

We leverage existing datasets of physiological outputs from different species to train a model that is physiologically-relevant and translatable across different experimental conditions.

  • Accurate
    Mean accuracy of 81% validated across several animal species and human populations.
  • Translatable
    Translatability testing between biosimulations between rats and humans show subtle and significant physiological differences that directly impact the PK/Pd.
  • Scalable
    Test over 1000s of compounds in a matter of hours and easily apply insights to large datasets without sacrificing accuracy!
BIOiSIMTM enables your team with a novel platform that focuses your development efforts on the drug compounds that are more likely to deliver on the anticipated value for the treatment or cure of a specific disease.
Current With VeriSIM
~10 years/drug
<5 years/drug
Additional Benefits
  • Specific to desired output

    With our framework, we can quickly develop custom, specific models.

  • Multiple routes of administration

    We simulate various routes of administrations such as IV, oral, and transdermal and others.

  • Trained on diverse data across various animal and human species

    Validated with both FDA and proprietary compounds.

  • Rapid result generation

    Our platform is cloud-based and generates predictions in seconds.

  • Expanding feature set

    We are always adding new functionality and expanding the domain of applicability.

  • Self-learning

    Our model extracts conclusions from complex and convoluted data.

Read our latest published article describing the tech Download Publication
3R's: Refinement, Reduction, Replacement
  • Refinement
    BIOiSIM enables researchers to select only the most human-relevant preclinical testing subjects by providing species-translatable simulation outputs.
  • Reduction
    The BIOiSIM platform can run simulations of 1000's of experimental conditions in vivo, decreasing reliance on animal tests.
  • Replacement
    By leveraging existing datasets, BIOiSIM enables researchers to make assessment of drug disposition without any animal experimentation.
Our Customers
Pecus ac blandit oppeto dolus oppeto in saluto. Enim montes tation obruo tristique acsi penatibus ne vehicula.
  • Save millions of dollars in R&D while drastically reducing the need for excessive and unreliable animal clinical trials.
    Recognize an average cost reduction of 50%
  • Save years of time identifying compounds for potential treatment options and cure for diseases
    Save years by narrowing the sample size of which compounds to test
  • Recognize accuracy and efficiency, far beyond what’s seen in animal testing
    Improvements in efficiency and an increase in the number of new successful formulas

Give your development pipeline an edge

Speak to one of our experts today